Why Bernie Sanders’ Ozempic crusade is misguided


Wouldn’t it be nice if we didn’t have to pay for the things we want?

That’s the long and short of U.S. Sen. Bernie Sanders’ latest harebrained scheme to cut drug prices. In the Vermont independent’s capacity as chairman of the Senate Health, Education, Labor and Pensions Committee, Sanders sent a letter to the CEO of Novo Nordisk last April demanding he explain the “outrageously high prices his pharmaceutical company is charging for” the diabetes drug Ozempic and the weight loss drug Wegovy.

It’s not surprising that Sanders, one of the most vociferous critics of the pharmaceutical industry in Congress, would take such a critical approach. What’s more shocking is the research that inspired Sanders’ crusade — a study published in the Journal of the American Medical Association that argues drug prices should be closer to what it costs companies to manufacture them.

Click to read the full article in The Dallas Morning News. 

Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.

Scroll to Top